Search results for "Triptorelin"

showing 4 items of 14 documents

Prolactin secretion before, during, and after chronic gonadotropin-releasing hormone agonist treatments in children.

2005

Objective To examine the effect of long-term administration of GnRH agonists (GnRHa) on PRL secretion in children affected by central precocious puberty (CPP) and growth hormone deficiency (GHD). Design Prospective analysis of blood sampling before, during, and after GnRHa treatments. Setting Pediatric endocrine center. Patient(s) One hundred nineteen and 93 children with a diagnosis of CPP and GHD, respectively. Intervention(s) Monthly depot injections of GnRHa drugs (leuprorelin acetate 3.75 mg [LA] and triptorelin 3.75 mg [TR]) administered to CPP and GHD patients for 40 and 24 months, respectively. Main Outcome Measure(s) Serum PRL levels at baseline and after 6, 12, 18, 24, 30, 36, and…

Malemedicine.medical_specialtymedicine.drug_classPuberty PrecociousGonadotropin-releasing hormoneGrowth hormone deficiencyGonadotropin-Releasing HormoneLeuprorelinInternal medicineGonadotropin-releasing hormone agonistmedicinePrecocious pubertyHumansProspective StudiesChildbusiness.industryHuman Growth HormoneObstetrics and Gynecologymedicine.diseaseTriptorelinProlactinProlactinEndocrinologyReproductive MedicineChild PreschoolFemalebusinessBlood samplingmedicine.drugFertility and sterility
researchProduct

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcome…

2016

Purpose The Suppression of Ovarian Function trial showed improved disease control for tamoxifen plus ovarian function suppression (OFS) compared with tamoxifen alone for the cohort of premenopausal patients who received prior chemotherapy. We present the patient-reported outcomes. Patients and Methods The quality-of-life (QoL) analysis includes 1,722 of 2,045 premenopausal patients with hormone receptor–positive breast cancer randomly assigned to receive adjuvant treatment with 5 years of tamoxifen plus OFS or tamoxifen alone. Chemotherapy use before enrollment was optional. Patients completed a QoL form consisting of global and symptom indicators at baseline, every 6 months for 24 months, …

OncologyAdultCancer Researchmedicine.medical_specialtymedicine.medical_treatmentOvaryBreast Neoplasmslaw.invention03 medical and health sciences0302 clinical medicineBreast cancerRandomized controlled trialQuality of lifelawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumans030212 general & internal medicineChemotherapyTriptorelin Pamoatebusiness.industryOvaryRepeated measures designORIGINAL REPORTSmedicine.diseaseAndrostadienesTamoxifenmedicine.anatomical_structureOncologyPremenopauseChemotherapy Adjuvant030220 oncology & carcinogenesisLymphatic MetastasisCohortQuality of LifeFemaleSelf ReportbusinessTamoxifenmedicine.drug
researchProduct

Análisis molecular de la valoración del intervalo de tiempo óptimo entre la administración de acetato de triptorelina y la punción folicular en los t…

2023

Los fármacos análogos de la GnRH y la hCG han demostrado ser igualmente eficaces en la activación de la cascada de intermediarios de la maduración final ovocitaria que ocurre tras el estímulo ovulatorio. Sin embargo, su mecanismo de acción y por tanto los perfiles hormonales hallados tras el estímulo de los dos fármacos son muy diferentes. El tiempo más adecuado para programar la recolección ovocitaria tras la administración de acetato de triptorelina podría no ser 36 horas como ampliamente se ha pautado en los tratamientos de FIV con hCG. Este intervalo de tiempo es sumamente importante para obtener la mayor proporción posible de ovocitos MII porque procesos como el inicio de la luteinizac…

lhfármacos análogos agonistas de la hormona liberadora de gonadotrofinaUNESCO::CIENCIAS DE LA VIDA::Biología humana ::Embriología humanafecundación in vitroampiregulinabetacelulinaphlda1UNESCO::QUÍMICA::Bioquímica ::Biología molecularprogesteronapcrtrigger 36hfisiología de la reproducción humana asistidaugp2marcadores moleculares no invasivos de madurez ovocitariahumanorgs2trigger 40htrigger 30hacetato de triptorelinaUNESCO::CIENCIAS MÉDICAS ::Farmacodinámica::Acción de los medicamentosepiregulinagnrhhormonasovocito metafase iiUNESCO::CIENCIAS DE LA VIDA::Fisiología humana ::Fisiología de la reproduccióncélulas de la granulosaelisalíquido folicularefnb2embriologíacyp19a1adamts9
researchProduct

Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.

2004

Today, androgen deprivation therapy is a cornerstone of treatment for advanced prostate cancer, although it presents important complications such as osteoporosis. Neridronate, a relatively new bisphosphonate, is able to prevent bone loss in patients with prostate cancer during androgen ablation. Introduction: Androgen-deprivation therapy (ADT) is a cornerstone of treatment for advanced prostate cancer. This therapy has iatrogenic complications, such as osteoporosis. The aim of our study was to evaluate the efficacy of neridronate, a relatively new bisphosphonate, to prevent bone loss during androgen ablation. Materials and Methods: Forty-eight osteoporotic patients with prostate cancer, tre…

musculoskeletal diseasesMalemedicine.medical_specialtyDeoxypyridinolineTime FactorsBicalutamideAntineoplastic Agents HormonalEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisUrologyBone and BonesAndrogen deprivation therapychemistry.chemical_compoundProstate cancerAbsorptiometry PhotonBone DensityMedicineNeridronic acidHumansOrthopedics and Sports MedicineAmino AcidsAgedCholecalciferolTriptorelin PamoateDiphosphonatesbusiness.industryProstatic NeoplasmsAndrogen AntagonistsBisphosphonatemedicine.diseaseAlkaline PhosphataseAndrogen deprivation therapy; Bisphosphonates; Neridronate; Osteoporosis; Prostate cancer; Absorptiometry Photon; Aged; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Androgens; Antineoplastic Agents Hormonal; Bone Density; Bone and Bones; Calcium; Cholecalciferol; Diphosphonates; Humans; Male; Osteoporosis; Prostatic Neoplasms; Time Factors; Triptorelin Pamoate; SurgerySurgerychemistryAndrogensOsteoporosisCalciumbusinessCholecalciferolmedicine.drugJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
researchProduct